Friday, September 29, 2023


Biotechnology News Magazine

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.

HIV RNA extracted from EDTA plasma or dried blood spots is analyzed with the assay to measure genomic mutations in the protease, reverse transcriptase and integrase regions of the pol gene. Data from these tests is intended to help inform global epidemiologic and genetic surveillance studies to track the ongoing evolution of the virus.

The kit is designed to support the detection of the UNAIDS 2030 95-95-95 HIV targets, which aims to have 95 percent of people living with HIV to be diagnosed, 95 percent who are diagnosed to be receiving treatment, and 95 percent of those on treatment to be virally suppressed. This enhanced research assay, which is compatible with the recently launched Applied Biosystems MagMAX Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Spots, provides laboratories with a standardized tool for drug resistance surveillance of HIV mutations to antiretroviral therapeutic inhibitors which can help identify global areas of need.

“A key factor in identifying new public health treatment strategies is knowledge of the viral resistance genotypes present in a given population as indicated by mutations measured in that population,” said Dr. Manoj Gandhi, senior medical director of genetic testing solutions at Thermo Fisher Scientific. “Monitoring for treatment-resistant strains of HIV can improve global understanding of HIV and help keep the world’s public health officials one step ahead of future developments.”

The Applied Biosystems HIV-1 Genotyping Kit will analyze expanded targets associated with HIV drug resistance that include mutations in the integrase region of the pol gene on Applied Biosystems Sanger sequencing CE instrumentation. It has been designed to offer broad Group M subtype coverage to address regions of the world with the greatest need such as Africa, Latin America, India and portions of Asia, where global health access pricing is available. More here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine